Are drug-eluting stents treatment for multivessel the preferred coronary artery disease?

Drug-eluting stents (DES) constitute a major breakthrougli in restenosis prevention after initial percutaneous coronary, intervention (PCI). Target lesion and vessel revascularization rates of <10% at six months follow-up represent a significant medical advance. Many cardiologists consider it reasonable to assume that PCI using DES ought to be considered equivalent, if not superior, to by,pass surgery. The argument made is that in previous randomized clinical trials comparing PCI to coronary, artery bypass, grafting, restenosis was the determining factor favoring surgery, an event that clinical experience suggests is no longer as frequent. In the absence of a definitive clinical trial to Support this view, how should the prudent, cutting edge cardiologist evaluate the data and manage their patients?